Latest News
Dr Howard Weiner, Chairman of the Tiziana Scientific Advisory Board, to give an interview on Bloomberg Markets at 1.50pm ET today
30 June 2021
NEW YORK & LONDON, June 30, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces an interview with the Chairman of its’ Scientific Advisory Board...
Result of Annual General Meeting
25 June 2021
Tiziana Life Sciences plc
(the "Company")
Result of Annual General Meeting
At the Annual General Meeting of the Company held at 10.00 a.m. on 25 June 2021, all of the resolutions were duly passed.
The results of the proxy voting will be available shortly...
Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
23 June 2021
NEW YORK & LONDON, June 23, 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces that it has signed an...
Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs
21 June 2021
NEW YORK & LONDON, June 21, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, is pleased to announce the appointment of Dr. Kevin Schutz,...
Tiziana Responds to UK Call for Development of Innovative ‘Take Home’ Treatments for COVID-19 Disease
17 June 2021
NEW YORK & LONDON, June 17, 2021 — Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases announces that it has submitted a grant to the United...
Posting of Notice of Annual General Meeting
02 June 2021
For immediate release
2 June 2021
The Company announces that a letter to Shareholders has been posted advising that the Notice of Annual General Meeting has been made available on the Company’s website: https://ir.tizianalifesciences.com/shareholder-services/annual-general-meeting
The AGM is to be held on...